['\xe2\x86\x93 = DECREASED (INDUCES LAMOTRIGINE GLUCURONIDATION).', '\xe2\x86\x91 = INCREASED (INHIBITS LAMOTRIGINE GLUCURONIDATION).', '? = CONFLICTING DATA.', 'CONCOMITANT\xc2\xa0DRUG', 'EFFECT\xc2\xa0ON\xc2\xa0CONCENTRATION OF\xc2\xa0LAMOTRIGINE\xc2\xa0OR CONCOMITANT\xc2\xa0DRUG', 'CLINICAL\xc2\xa0COMMENT', 'ESTROGEN-CONTAINING\xc2\xa0ORAL CONTRACEPTIVE\xc2\xa0PREPARATIONS CONTAINING\xc2\xa030\xc2\xa0MCG ETHINYLESTRADIOL\xc2\xa0AND\xc2\xa0150\xc2\xa0MCG LEVONORGESTREL', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE \xe2\x86\x93\xc2\xa0LEVONORGESTREL', 'DECREASED\xc2\xa0LAMOTRIGINE\xc2\xa0LEVELS APPROXIMATELY\xc2\xa050%. DECREASE\xc2\xa0IN\xc2\xa0LEVONORGESTREL COMPONENT\xc2\xa0BY\xc2\xa019%.', 'CARBAMAZEPINE\xc2\xa0AND CARBAMAZEPINE\xc2\xa0EPOXIDE', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE ?\xc2\xa0CARBAMAZEPINE EPOXIDE', 'ADDITION\xc2\xa0OF\xc2\xa0CARBAMAZEPINE DECREASES\xc2\xa0LAMOTRIGINE CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%. MAY\xc2\xa0INCREASE\xc2\xa0CARBAMAZEPINE EPOXIDE\xc2\xa0LEVELS.', 'PHENOBARBITAL/PRIMIDONE', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%.', 'PHENYTOIN', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%.', 'RIFAMPIN', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE AUC\xc2\xa0APPROXIMATELY\xc2\xa040%.', 'VALPROATE', '\xe2\x86\x91\xc2\xa0LAMOTRIGINE ?\xc2\xa0VALPROATE', 'INCREASED\xc2\xa0LAMOTRIGINE CONCENTRATIONS\xc2\xa0SLIGHTLY\xc2\xa0MORE\xc2\xa0THAN 2-FOLD. DECREASED\xc2\xa0VALPROATE\xc2\xa0CONCENTRATIONS AN\xc2\xa0AVERAGE\xc2\xa0OF\xc2\xa025%\xc2\xa0OVER\xc2\xa0A\xc2\xa03-WEEK PERIOD\xc2\xa0THEN\xc2\xa0STABILIZED\xc2\xa0IN\xc2\xa0HEALTHY VOLUNTEERS;\xc2\xa0NO\xc2\xa0CHANGE\xc2\xa0IN\xc2\xa0CONTROLLED CLINICAL\xc2\xa0TRIALS\xc2\xa0IN\xc2\xa0EPILEPSY\xc2\xa0PATIENTS.']